SinoMab BioScience EV/EBITDA
What is the EV/EBITDA of SinoMab BioScience?
The EV/EBITDA of SinoMab BioScience Limited is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on HKSE compared to SinoMab BioScience
What does SinoMab BioScience do?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Companies with ev/ebitda similar to SinoMab BioScience
- Novavax has EV/EBITDA of N/A
- Cazaly Resources has EV/EBITDA of N/A
- DC Acquisition has EV/EBITDA of N/A
- Macarthur Minerals has EV/EBITDA of N/A
- Sierra Madre Gold and Silver has EV/EBITDA of N/A
- Rathdowney Resources has EV/EBITDA of N/A
- SinoMab BioScience has EV/EBITDA of N/A
- Big Dougie Capital has EV/EBITDA of N/A
- Income Trust has EV/EBITDA of N/A
- Aloro Mining has EV/EBITDA of N/A
- Manganese X has EV/EBITDA of N/A
- Coho Collective Kitchens has EV/EBITDA of N/A
- Viva Gold has EV/EBITDA of N/A